Biologics in Practice: Unique Opportunity for Allergist Expertise (MOC)
You can earn up to 2.0 AMA PRA Category 1 Credit(s)™. This activity has also been designated by the ABAI for 2.0 MOC Part II Self-Assessment credits. Cost:
$40 $20 for College Members, $60 $30 for non-members.
These presentations will review: 1) recent advances in our understanding of immune mechaninisms of asthma including roles of epithelial cells and epithelial cell derived cytokines and novel immune cell types including ELC2, ELC3, iNKT cells, gd cells, and Th17 cells; 2) the therapeutic potential of immune response modifiers (IRMs); discussion of strategies to optimize treatment with IRMs including the role of personalized medicine; and discuss patient-specific features that can influence IRMs' therapeutic benefits; and 3) presentations and management of hypersensitivity reactions to biologics.
Release Date: 12/15/2015
Expiration Date: 12/14/2018
The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The American College of Allergy, Asthma & Immunology (ACAAI) designates this enduring material for a maximum of 2 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
• Discuss phenotypes and endotypes in the context of the patient with severe asthma
• Describe the relative advantages and disadvantages associated with various asthma pharmacotherapies, particularly biologics
• Discuss the side effect profiles of the various new therapies and how to go about handling such complications
Rohit K. Katial, MD, FACAAI
James L. Sublett, MD, FACAAI
Larry Borish, MD, FACAAI
Thomas B. Casale, MD, FACAAI
David A. Khan, MD, FACAAI
- 2.00 AMA PRA Category 1 Credit™
- 2.00 Attendance
- 2.00 MOC